Immunogenicity of 4-dose Essen intramuscular regimen for rabies post-exposure prophylaxis: A multi-center cross-sectional study in China

IF 6.3 3区 医学 Q1 INFECTIOUS DISEASES
Qisheng Hou , Si Liu , Cheng Liu , Xu Wang , Jirong Shi , Qingjun Chen , Xinjun Lv , Zhenggang Zhu , Chuanlin Wang , Wenwu Yin
{"title":"Immunogenicity of 4-dose Essen intramuscular regimen for rabies post-exposure prophylaxis: A multi-center cross-sectional study in China","authors":"Qisheng Hou ,&nbsp;Si Liu ,&nbsp;Cheng Liu ,&nbsp;Xu Wang ,&nbsp;Jirong Shi ,&nbsp;Qingjun Chen ,&nbsp;Xinjun Lv ,&nbsp;Zhenggang Zhu ,&nbsp;Chuanlin Wang ,&nbsp;Wenwu Yin","doi":"10.1016/j.tmaid.2024.102735","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The 4-dose Essen intramuscular (IM) regimen for rabies post-exposure prophylaxis (PEP) has been recommended by Advisory Committee on Immunization Practices (ACIP) and World Health Organization (WHO), but the large-sample clinical evidence is still limited.</p></div><div><h3>Method</h3><p>Rabies virus neutralizing antibodies of 11,752 patients were detected from 409 rabies prevention clinics in 27 provinces in China. Patients with serum collected before or no later than 1 h after injection on the day of the fifth dose (day 28) of 5-dose Essen regimen were included in Group A to observe the immune efficacy of 4-dose Essen IM regimen, and patients with serum collected 14–28 days after injection of the fifth dose were included in Group B to observe the immune efficacy of 5-dose Essen IM regimen.</p></div><div><h3>Results</h3><p>Finally, 2351 cases met the inclusion and exclusion criteria, including 2244 cases in Group A and 107 cases in Group B. The antibody titer of Group A was higher than that of Group B [12.21 (4.15, 32.10) IU/ml <em>vs.</em> 9.41 (3.87, 27.38) IU/ml] (<em>P</em> = 0.002). In Group A, the median antibody titers were 4.01IU/ml, 11.63IU/ml and 29.46IU/ml in patients vaccinated with purified hamster kidney cell vaccine (PHKCV), purified Vero cell vaccine (PVRV), and human diploid cell rabies vaccine (HDCV), respectively, with statistical significance (<em>P</em> &lt; 0.001).</p></div><div><h3>Conclusions</h3><p>The 4-dose Essen IM regimen could provide satisfactory immune effect, and HDCV induced higher antibody titer than PHKCV or PVRV.</p></div>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"60 ","pages":"Article 102735"},"PeriodicalIF":6.3000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1477893924000516/pdfft?md5=8b2fe93044c079ef9915e86c4cd6a62a&pid=1-s2.0-S1477893924000516-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Travel Medicine and Infectious Disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1477893924000516","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The 4-dose Essen intramuscular (IM) regimen for rabies post-exposure prophylaxis (PEP) has been recommended by Advisory Committee on Immunization Practices (ACIP) and World Health Organization (WHO), but the large-sample clinical evidence is still limited.

Method

Rabies virus neutralizing antibodies of 11,752 patients were detected from 409 rabies prevention clinics in 27 provinces in China. Patients with serum collected before or no later than 1 h after injection on the day of the fifth dose (day 28) of 5-dose Essen regimen were included in Group A to observe the immune efficacy of 4-dose Essen IM regimen, and patients with serum collected 14–28 days after injection of the fifth dose were included in Group B to observe the immune efficacy of 5-dose Essen IM regimen.

Results

Finally, 2351 cases met the inclusion and exclusion criteria, including 2244 cases in Group A and 107 cases in Group B. The antibody titer of Group A was higher than that of Group B [12.21 (4.15, 32.10) IU/ml vs. 9.41 (3.87, 27.38) IU/ml] (P = 0.002). In Group A, the median antibody titers were 4.01IU/ml, 11.63IU/ml and 29.46IU/ml in patients vaccinated with purified hamster kidney cell vaccine (PHKCV), purified Vero cell vaccine (PVRV), and human diploid cell rabies vaccine (HDCV), respectively, with statistical significance (P < 0.001).

Conclusions

The 4-dose Essen IM regimen could provide satisfactory immune effect, and HDCV induced higher antibody titer than PHKCV or PVRV.

用于狂犬病暴露后预防的四剂埃森肌肉注射方案的免疫原性:一项在中国进行的多中心横断面研究。
背景:狂犬病暴露后预防(PEP)的4剂埃森肌肉注射(IM)方案已被免疫实践咨询委员会(ACIP)和世界卫生组织(WHO)推荐,但大样本临床证据仍然有限:方法:在中国 27 个省的 409 个狂犬病预防门诊检测了 11,752 名患者的狂犬病毒中和抗体。方法:从中国 27 个省的 409 家狂犬病预防门诊中检测出 11 752 例狂犬病患者的狂犬病毒中和抗体,将 5 剂埃森方案注射第 5 剂(第 28 天)前或注射后 1 小时内采集血清的患者纳入 A 组,观察 4 剂埃森 IM 方案的免疫效果;将注射第 5 剂 14-28 天后采集血清的患者纳入 B 组,观察 5 剂埃森 IM 方案的免疫效果:A组的抗体滴度高于B组[12.21 (4.15, 32.10) IU/ml vs. 9.41 (3.87, 27.38) IU/ml](P=0.002)。在 A 组中,接种纯化仓鼠肾细胞疫苗(PHKCV)、纯化 Vero 细胞疫苗(PVRV)和人二倍体细胞狂犬病疫苗(HDCV)的患者的抗体滴度中位数分别为 4.01IU/ml、11.63IU/ml 和 29.46IU/ml,具有统计学意义(PConclusions:4剂埃森IM方案可提供令人满意的免疫效果,HDCV诱导的抗体滴度高于PHKCV或PVRV。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Travel Medicine and Infectious Disease
Travel Medicine and Infectious Disease PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-INFECTIOUS DISEASES
CiteScore
19.40
自引率
1.70%
发文量
211
审稿时长
49 days
期刊介绍: Travel Medicine and Infectious Disease Publication Scope: Publishes original papers, reviews, and consensus papers Primary theme: infectious disease in the context of travel medicine Focus Areas: Epidemiology and surveillance of travel-related illness Prevention and treatment of travel-associated infections Malaria prevention and treatment Travellers' diarrhoea Infections associated with mass gatherings Migration-related infections Vaccines and vaccine-preventable disease Global policy/regulations for disease prevention and control Practical clinical issues for travel and tropical medicine practitioners Coverage: Addresses areas of controversy and debate in travel medicine Aims to inform guidelines and policy pertinent to travel medicine and the prevention of infectious disease Publication Features: Offers a fast peer-review process Provides early online publication of accepted manuscripts Aims to publish cutting-edge papers
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信